

Supplemental Table 1. Prospective cohort studies and corresponding methodologic references

Prospective Cohort	Abbreviation	Reference*
Alpha-Tocopherol Beta-Carotene Cancer Prevention Study	ATBC	(1)
American Cancer Society Cancer Prevention Study-II	CPS II	(2)
CLUE II	-	(3)
European Prospective Investigation into Cancer and Nutrition Study	EPIC	(4)
Health Professional's Follow-up Study	HPFS	(5)
New York University Women's Health Study	NYUWHS	(6)
Nurses' Health Study	NHS	(7)
Physicians' Health Study I	PHS	(8)
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial	PLCO	(9)
Shanghai Men's and Women's Health Study	SMWHS	(10, 11)
Women's Health Initiative	WHI	(12)
Women's Health Study	WHS	(13)

* References

1. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. *Ann Epidemiol* 1994;4:1-10.
2. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. *Cancer* 2002;94:2490-2501.
3. Gallicchio L, Chang H, Christo DK, et al. Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland. *Am J Epidemiol* 2008;167:807-13.
4. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5:1113-24.
5. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *J Natl Cancer Inst* 2005;97:1688-94.
6. Zeleniuch-Jacquotte A, Gu Y, Shore RE, et al. Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. *Int J Cancer* 2005;114:323-7.
7. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. *Nat Rev Cancer* 2005;5:388-96.
8. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. *J Natl Cancer Inst* 2004;96:546-53.
9. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO trial. *Mutat Res* 2005;592:147-54.

10. Zheng W, Chow WH, Yang G, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. *Am J Epidemiol* 2005;162:1123-31.
11. Xu WH, Zhang XL, Gao YT, et al. Joint effect of cigarette smoking and alcohol consumption on mortality. *Prev Med* 2007;45:313-19.
12. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. *Ann Epidemiol* 2003;13:S5-17.
13. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. *J Womens Health Gend Based Med* 2000;9:19-27.

Supplemental Table 2. Characteristics of pancreatic cancer cases and matched controls

Characteristic	Cases	Controls
No. of participants	1534	1583
Mean age (years, +/- SD)*	68.6 +/- 8.5	69.3 +/- 7.8
Female gender (%)*	52.7	51.7
White race/ethnicity (%)*	90.4	91.9
Cohort (No. [%])*		
ATBC	193 (12.6)	208 (13.1)
CLUE II	68 (4.4)	71 (4.5)
CPS II	124 (8.1)	118 (7.5)
EPIC	421 (27.4)	428 (27.0)
HPFS	54 (3.5)	52 (3.3)
NHS	82 (5.4)	84 (5.3)
NYU-WHS	13 (0.9)	13 (0.8)
PHS I	49 (3.2)	54 (3.4)
PLCO	203 (13.2)	219 (13.8)
SMWHS	58 (3.8)	65 (4.1)
WHI	244 (15.9)	239 (15.1)
WHS	25 (1.6)	32 (2.0)
Smoking status (%)†		
Current	27.3	22.9
Past	32.5	34.4
Never	37.4	41.2
Unknown	2.9	1.5
Mean body-mass index (kg/m ² , +/- SD)	26.6 +/- 4.5	26.4 +/- 4.5
History of diabetes mellitus (%)	9.6	6.5
Genotype-derived ABO blood groups (%)		
Blood Type	Alleles	
O	O, O	33.3
A		45.6
	A, O	36.1
	A, A	9.5
AB	A, B	6.3
B		14.7
	B, O	12.9
	B, B	1.8

Abbreviations: ATBC, Alpha-Tocopherol Beta-Carotene, Cancer Prevention Study; CPS II, American Cancer Society Cancer Prevention Study-II; EPIC, European Prospective Investigation into Cancer and Nutrition Study; HPFS, Health Professional's Follow-up

Study; NYUWHS, New York University Women's Health Study; NHS, Nurses' Health Study; PHS, Physicians' Health Study I; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SMWHS, Shanghai Men's and Women's Health Study; WHI, Women's Health Initiative; WHS, Women's Health Study; SD, standard deviation.

* Cases and controls matched on covariate.

† Cases and controls matched on smoking status in HPFS, NHS, PHS, and WHS.

Supplemental Table 3. Risk of incident pancreatic cancer by genotype-derived ABO blood type and stratified by other predisposing factors

Characteristic	Cases/ Controls	Genotype-derived ABO Blood Type Odds Ratio (95% confidence interval)*				<i>P</i> - interaction
		O	A	AB	B	
Age						0.53
≤ 65 years	525 / 461	1.0	1.16 (0.87-1.55)	1.99 (1.05-3.75)	1.41 (0.90-2.20)	
66 – 75 years	679 / 775	1.0	1.59 (1.25-2.03)	1.37 (0.88-2.13)	1.63 (1.17-2.26)	
> 75 years	330 / 347	1.0	1.39 (0.98-1.97)	1.36 (0.65-2.85)	1.57 (0.95-2.59)	
Gender						0.54
Women	809 / 819	1.0	1.36 (1.09-1.70)	1.34 (0.84-2.13)	1.31 (0.94-1.81)	
Men	725 / 764	1.0	1.38 (1.09-1.76)	1.57 (1.00-2.45)	1.76 (1.26-2.44)	
Race/ethnicity						0.97
White	1386 / 1455	1.0	1.38 (1.17-1.63)	1.45 (1.03-2.04)	1.54 (1.20-1.97)	
Non-White	114 / 118	1.0	1.42 (0.71-2.83)	1.62 (0.63-4.19)	1.47 (0.73-2.99)	
Smoking status						0.33
Never / Quit date ≥ 5 years	887 / 1036	1.0	1.41 (1.15-1.73)	1.31 (0.87-1.98)	1.35 (1.00-1.82)	
Current / Quit date < 5 years or unknown	603 / 524	1.0	1.38 (1.04-1.82)	1.84 (1.09-3.11)	1.90 (1.28-2.81)	
Body-mass index						0.95
< 25 kg/m ²	587 / 671	1.0	1.48 (1.14-1.91)	1.69 (1.06-2.70)	1.55 (1.07-2.23)	
25-29.9 kg/m ²	639 / 605	1.0	1.37 (1.06-1.77)	1.23 (0.72-2.10)	1.40 (0.96-2.05)	
> 30 kg/m ²	294 / 297	1.0	1.25 (0.86-1.82)	1.41 (0.63-3.15)	1.76 (1.03-2.99)	

* Multivariable adjustment by age, gender, race/ethnicity, cohort, smoking status, body-mass index, and history of diabetes mellitus, excluding the stratification covariate.